文献速递心力衰竭与心肌病

恩格列净对射血分数降低心衰患者左室容积、质量及功能的影响:EMPIRE HF 试验子研究

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该研究为 EMPIRE HF 随机临床试验的探索性事后分析,纳入 190 例稳定 HFrEF 且射血分数≤40% 的患者,随机接受恩格列净 10 mg 每日一次或安慰剂治疗 12 周。结果显示恩格列净显著降低左室收缩末期容积指数、舒张末期容积指数、左房容积指数及左室质量指数,但左室射血分数无变化。

要点

  • 恩格列净治疗 12 周可 modestly 降低左室收缩末期和舒张末期容积指数及左房容积指数。
  • 恩格列净显著降低左室质量指数,但左室射血分数无显著改变。
  • 上述心脏重构改善在各亚组中表现一致,但研究样本量小、随访短。

核心结论

  • 在小型短期随机研究中,恩格列净与左室和左房容积的适度降低相关,与射血分数无关联。
  • SGLT2i 使用超过 12 周的效果需进一步研究。

研究设计与样本

  • 探索性事后分析,纳入稳定 HFrEF 且射血分数≤40% 的患者,随机 1:1 接受恩格列净 10 mg 每日一次或匹配安慰剂,治疗 12 周。
  • 共随机 190 例患者(恩格列净组和安慰剂组各 95 例),平均(SD)年龄 64(11)岁,162 例(85.3%)为男性,97 例(51.1%)为缺血性 HFrEF,24 例(12.6%)有 2 型糖尿病,平均(SD)最近记录的左室射血分数为 29%(8%)。
  • 186 例完成研究,随访至 12 周。

主要发现

  • 与安慰剂相比,恩格列净显著降低左室收缩末期容积指数(-4.3 [95% CI, -8.5 至 -0.1] mL/m2;P = .04)。
  • 恩格列净显著降低左室舒张末期容积指数(-5.5 [95% CI, -10.6 至 -0.4] mL/m2;P = .03)。
  • 恩格列净显著降低左房容积指数(-2.5 [95% CI, -4.8 至 -0.1] mL/m2;P = .04)。
  • 左室射血分数无显著变化(1.2% [95% CI, -1.2% 至 3.6%];P = .32)。
  • 恩格列净显著降低左室质量指数(-9.0 [95% CI, -17.2 至 -0.8] g/m2;P = .03)。

临床怎么用

  • 对于稳定 HFrEF 患者,恩格列净治疗 12 周可适度改善左室和左房重构,但射血分数未见改变。
  • 该研究为探索性事后分析,样本量小且随访短,临床决策应结合主要终点证据。

局限性

  • 探索性事后分析,样本量小(190 例),随访时间短(12 周)。
  • 结果需在更长疗程和更大样本中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in patients with heart failure and a reduced ejection fraction (HFrEF). The association with cardiac remodeling has not been investigated. OBJECTIVE: To investigate the outcome of the SGLT2i empagliflozin, compared with placebo, on cardiac remodeling in patients with HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This exploratory post hoc analysis included participants with stable HFrEF and ejection fractions of 40% or less, who were randomly enrolled in an investigator-initiated, multicenter, double-blind, placebo-controlled randomized clinical trial in Denmark. Enrollment commenced on June 29, 2017, and continued through September 10, 2019, with the last participant follow-up on December 20, 2019. INTERVENTIONS: Randomization (1:1) to empagliflozin (10 mg once daily) or matching placebo in addition to recommended heart failure therapy for 12 weeks. MAIN OUTCOMES AND MEASURES: Efficacy measures were changes from baseline to week 12 in left ventricular end-systolic and end-diastolic volume indexes, left atrial volume index, and left ventricular ejection fraction adjusted for age, sex, type 2 diabetes, and atrial fibrillation. Secondary efficacy measures included changes in left ventricular mass index, global longitudinal strain, and relative wall thickness. RESULTS: A total of 190 patients were randomized (95 each receiving empagliflozin and placebo), with a mean (SD) age of 64 (11) years; 162 were men (85.3%), 97 (51.1%) had ischemic HFrEF, 24 (12.6%) had type 2 diabetes, and the mean (SD) latest recorded left ventricular ejection fraction was 29% (8%). Of the 190, 186 completed the study. Empagliflozin significantly reduced left ventricular end-systolic volume index (-4.3 [95% CI, -8.5 to -0.1] mL/m2; P = .04), left ventricular end-diastolic volume index (-5.5 [95% CI, -10.6 to -0.4] mL/m2; P = .03), and left atrial volume index (-2.5 [95% CI, -4.8 to -0.1] mL/m2; P = .04) compared with placebo at 12 weeks' follow-up, with no change in left ventricular ejection fraction (1.2% [95% CI, -1.2% to 3.6%]; P = .32). These findings were consistent across subgroups. Of secondary efficacy measures, left ventricular mass index was significantly reduced by empagliflozin (-9.0 [95% CI, -17.2 to -0.8] g/m2; P = .03). CONCLUSIONS AND RELEVANCE: In this small, randomized, short-term study, empagliflozin was associated with modest reductions in left ventricular and left atrial volumes with no association with ejection fraction. Effects beyond 12 weeks of SGLT2i use require further study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03198585.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Omar M, Jensen J, Ali M, et al. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 33404637. doi:10.1001/jamacardio.2020.6827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。